NCT05440786 2026-04-13
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Eli Lilly and Company
Phase 2 Active not recruiting
Clinical Trials
29 trialsNCT05691491 2026-04-13
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT05004116 2026-03-04
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT00080938 2023-06-29
Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT05858177 2023-05-15
MPPGL
Peking Union Medical College Hospital
Phase 2 Completed
NCT02049593 2022-09-26
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT00012116 2020-08-03
Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01051596 2019-04-02
A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
Georgetown University
Phase 2 Completed
NCT01284335 2019-01-10
A Safety Study in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT00617539 2018-04-20
Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
University of California, San Francisco
Phase 2 Completed
NCT00547131 2018-04-17
Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors
City of Hope Medical Center
Phase 1 Completed
NCT01009515 2017-10-18
Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00715793 2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2 Completed
NCT01736800 2017-09-19
Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT00925132 2017-07-02
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
University of Iowa
Phase 1/2 Terminated
NCT01409174 2017-05-31
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00034697 2017-05-23
Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00076856 2017-05-09
Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00068666 2016-12-15
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT00026494 2016-01-18
Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00395070 2013-09-13
A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
Vical
Phase 3 Completed
NCT00385398 2013-09-02
QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT00544284 2013-02-15
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
City of Hope Medical Center
Phase 1 Completed
NCT00020839 2012-09-24
Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated
NCT00238251 2012-06-05
Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases
Swiss Cancer Institute
Phase 2 Completed
NCT00629187 2012-04-27
CN-306
Tufts Medical Center
Phase 1 Terminated
NCT00609011 2010-08-23
Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma
Myrexis Inc.
Phase 1/2 Completed
NCT00875355 2009-08-26
Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00268684 2006-02-28
Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC
Tel-Aviv Sourasky Medical Center
Phase 3 Unknown